PCSK9 and atherosclerosis: These data rule out direct mechanisms of PCSK-9 inhibition on lipidomic modifications and argue for a multifaceted system leading to vascular improvement in users of PCSK-9 inhibitors, in line with clinical data showing subclinical atherosclerosis regression documented in patients receiving a PCSK-9 inhibitor [37,38].